Avalyn Pharma (NASDAQ:AVLN) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Avalyn Pharma (NASDAQ:AVLN) from a hold rating to a sell rating in a research report released on Sunday,Wall Street Zen reports.

AVLN has been the subject of several other reports. Weiss Ratings began coverage on Avalyn Pharma in a report on Thursday, August 13th. They set a “sell (d+)” rating for the company. Evercore assumed coverage on shares of Avalyn Pharma in a research note on Tuesday, May 26th. They issued an “outperform” rating and a $51.00 target price on the stock. Zacks Research upgraded shares of Avalyn Pharma to a “hold” rating in a research report on Wednesday, May 27th. Jefferies Financial Group started coverage on shares of Avalyn Pharma in a research note on Monday, May 25th. They set a “buy” rating and a $52.00 price target for the company. Finally, Morgan Stanley increased their price objective on shares of Avalyn Pharma from $53.00 to $57.00 and gave the company an “overweight” rating in a report on Thursday, August 13th. Two investment analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Avalyn Pharma has an average rating of “Moderate Buy” and an average price target of $60.00.

Avalyn Pharma Stock Performance

Shares of AVLN opened at $31.52 on Friday. The company has a fifty day moving average price of $33.33. The company has a market cap of $1.40 billion and a price-to-earnings ratio of -1.38. Avalyn Pharma has a 52 week low of $24.15 and a 52 week high of $40.17. The company has a debt-to-equity ratio of 0.04, a current ratio of 33.12 and a quick ratio of 33.12.

Avalyn Pharma (NASDAQ:AVLN) last released its earnings results on Wednesday, August 12th. The company reported ($0.98) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.05. As a group, research analysts forecast that Avalyn Pharma will post -3.81 EPS for the current year.

Hedge Funds Weigh In On Avalyn Pharma

Several hedge funds have recently added to or reduced their stakes in the stock. Montanova Capital LLC bought a new position in Avalyn Pharma during the second quarter worth about $82,402,000. Bank of New York Mellon Corp bought a new stake in shares of Avalyn Pharma in the 2nd quarter valued at about $1,321,000. Finally, Braidwell LP bought a new stake in shares of Avalyn Pharma in the 2nd quarter valued at about $26,382,000.

About Avalyn Pharma

Avalyn Pharma is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for serious and progressive pulmonary diseases. The company is working to deliver established antifibrotic medicines directly to the lungs through proprietary inhalation technologies, with the goal of improving treatment and potentially reducing systemic exposure and related side effects.

Avalyn’s lead program, AP01, is an inhaled formulation of pirfenidone being developed for patients with idiopathic pulmonary fibrosis, a chronic lung disease characterized by progressive scarring and declining respiratory function.